- Home
- TSHA vs NRC Comparison
TSHA vs NRC Comparison
Compare TSHA & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | NRC |
|---|---|---|
| Founded | 2019 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 390.8M |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | TSHA | NRC |
|---|---|---|
| Price | $4.41 | $17.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.78 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 92.5K |
| Earning Date | 05-14-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.77% |
| EPS Growth | 5.56 | ★ 4707.69 |
| EPS | N/A | ★ 50.00 |
| Revenue | $9,773,000.00 | ★ $119,686,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $637.76 | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | ★ 17.28 | 1.81 |
| 52 Week Low | $1.13 | $9.76 |
| 52 Week High | $6.02 | $22.79 |
Technical Indicators
Market Signals| Indicator | TSHA | NRC |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 59.94 |
| Support Level | $4.33 | $14.48 |
| Resistance Level | $5.31 | $18.29 |
| Average True Range (ATR) | 0.26 | 0.85 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 51.82 | 60.10 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The company operates in the United States and Canada, of which key revenue is derived from the United States.